| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ... The Lancet 368 (9544), 1329-1338, 2006 | 3306 | 2006 |
| Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib TF Chu, MA Rupnick, R Kerkela, SM Dallabrida, D Zurakowski, L Nguyen, ... The Lancet 370 (9604), 2011-2019, 2007 | 1273 | 2007 |
| Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors CP Raut, M Posner, J Desai, JA Morgan, S George, D Zahrieh, ... Journal of Clinical Oncology 24 (15), 2325-2331, 2006 | 600 | 2006 |
| Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors J Desai, L Yassa, E Marqusee, S George, MC Frates, MH Chen, ... Annals of internal medicine 145 (9), 660-664, 2006 | 487 | 2006 |
| Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure S George, JY Blay, PG Casali, A Le Cesne, P Stephenson, SE Deprimo, ... European journal of cancer 45 (11), 1959-1968, 2009 | 465 | 2009 |
| Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors AJ Wagner, I Malinowska-Kolodziej, JA Morgan, W Qin, CDM Fletcher, ... Journal of clinical oncology 28 (5), 835-840, 2010 | 462 | 2010 |
| Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas S George, P Merriam, RG Maki, AD Van den Abbeele, JT Yap, T Akhurst, ... Journal of Clinical Oncology 27 (19), 3154-3160, 2009 | 381 | 2009 |
| Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial S George, Q Wang, MC Heinrich, CL Corless, M Zhu, JE Butrynski, ... Journal of Clinical Oncology 30 (19), 2401-2407, 2012 | 312 | 2012 |
| Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study E Ben‐Ami, CM Barysauskas, S Solomon, K Tahlil, R Malley, M Hohos, ... Cancer 123 (17), 3285-3290, 2017 | 224 | 2017 |
| Breakpoints of the t (11; 18)(q21; q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18 JA Morgan, Y Yin, AD Borowsky, F Kuo, N Nourmand, JI Koontz, ... Cancer research 59 (24), 6205-6213, 1999 | 221 | 1999 |
| A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib TV Patel, JA Morgan, GD Demetri, S George, RG Maki, M Quigley, ... Journal of the National Cancer Institute 100 (4), 282-284, 2008 | 217 | 2008 |
| Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors R Quek, Q Wang, JA Morgan, GI Shapiro, JE Butrynski, N Ramaiya, ... Clinical Cancer Research 17 (4), 871-879, 2011 | 190 | 2011 |
| Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure GD Demetri, MC Heinrich, JA Fletcher, CDM Fletcher, ... Clinical Cancer Research 15 (18), 5902-5909, 2009 | 182 | 2009 |
| Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors GD Demetri, P Lo Russo, IRJ MacPherson, D Wang, JA Morgan, ... Clinical Cancer Research 15 (19), 6232-6240, 2009 | 180 | 2009 |
| Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy E Choy, JE Butrynski, DC Harmon, JA Morgan, S George, AJ Wagner, ... BMC cancer 14, 1-6, 2014 | 177 | 2014 |
| Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors J Desai, S Shankar, MC Heinrich, JA Fletcher, CD Fletcher, J Manola, ... Clinical Cancer Research 13 (18), 5398-5405, 2007 | 164 | 2007 |
| SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic … GD Demetri, J Desai, JA Fletcher, JA Morgan, CDM Fletcher, ... Journal of Clinical Oncology 22 (14_suppl), 3001-3001, 2004 | 163 | 2004 |
| A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors P Schöffski, P Reichardt, JY Blay, H Dumez, JA Morgan, I Ray-Coquard, ... Annals of oncology 21 (10), 1990-1998, 2010 | 151 | 2010 |
| Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) RG Maki, JA Fletcher, MC Heinrich, JA Morgan, S George, J Desai, ... Journal of Clinical Oncology 23 (16_suppl), 9011-9011, 2005 | 141 | 2005 |
| Leiomyosarcoma of the inferior vena cava: survival after aggressive management H Ito, JL Hornick, MM Bertagnolli, S George, JA Morgan, EH Baldini, ... Annals of surgical oncology 14, 3534-3541, 2007 | 138 | 2007 |
